Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

por Schmid, Ulrike, Liesenfeld, Karl-Heinz, Fleury, Angele, Dallinger, Claudia, Freiwald, Matthias
Publicado 2017

Pharmacometric Characterization of Dabigatran Hemodialysis

por Liesenfeld, Karl-Heinz, Staab, Alexander, Härtter, Sebastian, Formella, Stephan, Clemens, Andreas, Lehr, Thorsten
Publicado 2013

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic simi...

por Kang, Jia, Eudy‐Byrne, Rena J., Mondick, John, Knebel, William, Jayadeva, Girish, Liesenfeld, Karl‐Heinz
Publicado 2020

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled...

por Moschetti, Viktoria, Desch, Michael, Goetz, Sophia, Liesenfeld, Karl-Heinz, Rosenbrock, Holger, Kammerer, Klaus-Peter, Wunderlich, Glen, Wind, Sven
Publicado 2017

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokine...

por Moschetti, Viktoria, Schlecker, Christina, Wind, Sven, Goetz, Sophia, Schmitt, Holger, Schultz, Armin, Liesenfeld, Karl-Heinz, Wunderlich, Glen, Desch, Michael
Publicado 2018

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

por Johnston, Curtis K., Eudy-Byrne, Rena J., Elmokadem, Ahmed, Nock, Valerie, Marquard, Jan, Soleymanlou, Nima, Riggs, Matthew M., Liesenfeld, Karl-Heinz
Publicado 2021

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-...

por Desch, Michael, Schlecker, Christina, Hohl, Kathrin, Liesenfeld, Karl-Heinz, Chan, Tom, Müller, Fabian, Wunderlich, Glen, Keller, Sascha, Ishiguro, Naoki, Wind, Sven
Publicado 2023

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

por Desch, Michael, Wunderlich, Glen, Goettel, Markus, Goetz, Sophia, Liesenfeld, Karl-Heinz, Chan, Tom S., Rosenbrock, Holger, Sennewald, Regina, Link, Jasmin, Keller, Sascha, Wind, Sven
Publicado 2021

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

por Menter, Alan, Cohen, Stanley, Kay, Jonathan, Strand, Vibeke, Gottlieb, Alice, Hanauer, Stephen, Eduru, Sravan Kumar, Buschke, Susanne, Lang, Benjamin, Liesenfeld, Karl-Heinz, Schaible, Jennifer, McCabe, Dorothy
Publicado 2022

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

por Rosenbrock, Holger, Desch, Michael, Kleiner, Oliver, Dorner‐Ciossek, Cornelia, Schmid, Bernhard, Keller, Sascha, Schlecker, Christina, Moschetti, Viktoria, Goetz, Sophia, Liesenfeld, Karl‐Heinz, Fillon, Gwenaelle, Giovannini, Riccardo, Ramael, Steven, Wunderlich, Glen, Wind, Sven
Publicado 2018

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

por Perkins, Bruce A., Soleymanlou, Nima, Rosenstock, Julio, Skyler, Jay S., Laffel, Lori M., Liesenfeld, Karl‐Heinz, Neubacher, Dietmar, Riggs, Matthew M., Johnston, Curtis K., Eudy‐Byrne, Rena J., Elmokadem, Ahmed, George, Jyothis T., Marquard, Jan, Nock, Valerie
Publicado 2020